Dr. Heinemann on Using Depth of Response in Pretreated Patients With CRC

Volker Heinemann, MD, PhD
Published: Monday, Aug 22, 2016


Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses using depth of response as an appropriate endpoint in studies examining patients with metastatic colorectal cancer (mCRC).

Depth of response is an important endpoint to measure when investigating triplet chemotherapy regimens, such as FOLFOXIRI, or the addition of an EGFR-targeted agent to a doublet-chemotherapy regimen in ROS1-positive patients, Heinemann explains.

It is here that depth of response, as well as tumor shrinkage, can be associated with overall survival, Heinmann says.

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses using depth of response as an appropriate endpoint in studies examining patients with metastatic colorectal cancer (mCRC).

Depth of response is an important endpoint to measure when investigating triplet chemotherapy regimens, such as FOLFOXIRI, or the addition of an EGFR-targeted agent to a doublet-chemotherapy regimen in ROS1-positive patients, Heinemann explains.

It is here that depth of response, as well as tumor shrinkage, can be associated with overall survival, Heinmann says.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x